PCV2 COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80MGATORVASTATINVS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME- AN ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN ORATORVASTATIN EVALUATION AND INFECTION THERAPY)
Abstract
Authors
J F Bobadilla M Garcia